株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

シャーガス病 (アメリカトリパノソーマ症) :世界の治験動向

Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 319594
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
シャーガス病 (アメリカトリパノソーマ症) :世界の治験動向 Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H1, 2017
出版日: 2017年05月31日 ページ情報: 英文 43 Pages
概要

当レポートでは、シャーガス病 (アメリカトリパノソーマ症) の治験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、治験を実施している主な製薬企業および研究機関のプロファイルなどをまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 主要国における治験件数:欧州
    • 主要国における治験件数:北米
    • 上位5ヶ国における治験件数:中南米

G7諸国における治験件数:シャーガス病 (アメリカトリパノソーマ症) 治験件数の感染症治験件数に対する比率

フェーズ (相) 別治験件数:G7諸国

E7諸国における治験件数:シャーガス病 (アメリカトリパノソーマ症) 治験件数の感染症治験件数に対する比率

フェーズ (相) 別治験件数:E7諸国

E7諸国における治験件数:フェーズ (相) 別

フェーズ (相) 別治験件数

  • フェーズ (相) 別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別治験件数

有望なスポンサー

治験主要参加企業 - シャーガス病 (アメリカトリパノソーマ症) 治療薬

有望な薬剤

治験プロファイルの基本情報

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4264CTIDB

GlobalData's clinical trial report, "Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H1, 2017" provides an overview of Chagas Disease (American Trypanosomiasis) clinical trials scenario. This report provides top line data relating to the clinical trials on Chagas Disease (American Trypanosomiasis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Five Countries Contributing to Clinical Trials in Central and South America 12
  • Clinical Trials by G7 Countries: Proportion of Chagas Disease (American Trypanosomiasis) to Infectious Disease Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 14
  • Clinical Trials by E7 Countries: Proportion of Chagas Disease (American Trypanosomiasis) to Infectious Disease Clinical Trials 15
  • Clinical Trials by Phase in E7 Countries 16
  • Clinical Trials in E7 Countries by Trial Status 17
  • Clinical Trials by Phase 18
  • In Progress Trials by Phase 19
  • Clinical Trials by Trial Status 20
  • Clinical Trials by End Point Status 21
  • Subjects Recruited Over a Period of Time 22
  • Clinical Trials by Sponsor Type 23
  • Prominent Sponsors 24
  • Top Companies Participating in Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials 25
  • Prominent Drugs 26
  • Clinical Trial Profile Snapshots 27

Appendix 41

  • Abbreviations 41
  • Definitions 41
  • Research Methodology 42
  • Secondary Research 42
  • About GlobalData 43
  • Contact Us 43
  • Source 43

List of Tables

List of Tables

  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Europe, Top Countries, 2017* 10
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 12
  • Proportion of Chagas Disease (American Trypanosomiasis) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 13
  • Chagas Disease (American Trypanosomiasis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Proportion of Chagas Disease (American Trypanosomiasis) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 15
  • Chagas Disease (American Trypanosomiasis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 16
  • Chagas Disease (American Trypanosomiasis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials by Phase, 2017* 18
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 19
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 20
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 21
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 22
  • Chagas Disease (American Trypanosomiasis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 23
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 24
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 25
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 26

List of Figures

List of Figures

  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Europe, Top Countries (%), 2017* 10
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 12
  • Proportion of Chagas Disease (American Trypanosomiasis) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 13
  • Chagas Disease (American Trypanosomiasis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Proportion of Chagas Disease (American Trypanosomiasis) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 15
  • Chagas Disease (American Trypanosomiasis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 16
  • Chagas Disease (American Trypanosomiasis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 18
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 19
  • Chagas Disease (American Trypanosomiasis) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 20
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 21
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 22
  • Chagas Disease (American Trypanosomiasis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 23
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 24
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 25
  • Chagas Disease (American Trypanosomiasis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 26
  • GlobalData Methodology 42
Back to Top